[시장보고서]세계 STD 진단 시장 : 규모, 점유율, 동향 분석 보고서 - 제품별, 용도별, 기술별, 검사 부위별, 지역별, 부문 예측(2024-2030년)

세계 STD 진단 시장 : 규모, 점유율, 동향 분석 보고서 - 제품별, 용도별, 기술별, 검사 부위별, 지역별, 부문 예측(2024-2030년)

STD Diagnostics Market Size, Share & Trends Analysis Report By Product, By Application, By Technology, By Location Of Testing, By Region, And Segment Forecasts, 2024 - 2030

상품코드 : 1433548

리서치사 : Grand View Research, Inc.

발행일 : 2024년 01월

페이지 정보 : 영문 156 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,275,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 9,666,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 12,447,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

STD 진단 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계 STD 진단 시장 규모는 2024년부터 2030년까지 복합 연간 성장률(CAGR) 7.18%로 확대될 전망이며 2030년에 163억 6,000만 달러에 이를 전망입니다.

성감염증(STD)의 질병 부담 증가, 젊은층의 인지도를 높이고 정기적인 스크리닝을 장려하는 정부,비영리 단체의 대처가, 시장 성장을 증대시키는 주요 요인입니다. WHO의 데이터에 따르면 매독, 임질, 클라미디아, 트리코모나스 등의 신규 감염자는 세계에서 매년 약 3억 7,400만 명에 이릅니다.

차세대 HIV 검사 키트 및 멀티플렉스 PCR 제품과 같은 고급 제품의 개발 및 상용화를 통해 의사는 다양한 STI를 적시에 진단 및 감별하고 적절한 치료를 할 수 있습니다. 한국에 본사를 둔 진단 회사 Seegene, Inc.는 다양한 원인 물질을 검출하는 Allplex, Anyplex, Seeplex 제품의 광범위한 포트폴리오를 제공합니다. 예를 들어, Allplex STI/BV Panel Assay는 한 번의 검사로 28개의 원인 물질을 구별할 수 있습니다. 2022년 4월, Seegene, Inc.는 Allplex HPV HR Detection의 개발을 발표했습니다.

Allplex HPV HR Detection은 세계 최초로 상업화된 '3 Ct' PCR 분석입니다. Seegene은 이 기술을 STI, 요로 감염(UTI) 및 호흡기 바이러스(RV) 분석을 포함한 전체 제품 체인에 적용하는 데 주력하고 있습니다. 이러한 전략적 기술적 진보는 성감염증(STD) 진단제 업계에서 회사의 점유율을 확대하는 데 더 많은 우위를 가져올 것으로 기대됩니다.

HIV 국가 전략 계획은 2030년까지 미국에서 인간 면역결핍 바이러스의 유행을 없애기 위한 로드맵입니다. 2021년부터 2025년까지 이어지는 이 HIV계획은 이 나라에 있어서 3번째 5개년 HIV국가계획으로, 2030년까지 인간 면역 결핍 바이러스의 신규 감염을 90% 반감시킨다는 10년 목표를 내걸고 있습니다. 또한, "바이러스성 간염 국가 전략 계획"에서는 성행위에 의해 감염되는 B형 간염과 C형 간염에 초점을 맞추었습니다. 2021년 1월, 미국 보건 사회 복지부(HHS)는 미국의 바이러스성 간염이 초래하는 예방 가능하고 실질적인 공중 보건 위협에 대처하기 위한 전국 전략을 발표했습니다. 정부의 유익한 행동은 STD 진단 산업의 확대에 유리한 분위기를 조성합니다.

각 회사는 신제품 개발 및 규제 당국의 승인을 지원하고 STD 진단 제품 포트폴리오를 강화하는 전략적 노력을 하고 있습니다. 예를 들어, 2020년 8월, DiaSorin, Inc.는 LIAISON XL MUREX anti-HBe의 도입에 대해 미국 FDA로부터 510(k) 승인을 취득했습니다. 이것은 HBV 감염의 진단에 사용됩니다. 이 immunoassay 제품은 화학 발광의 원리로 작동합니다.

성병 진단 시장 보고서 하이라이트

2023년 소모품 부문은 최대 시장 점유율을 차지하며, STD 진단을 위한 높은 검사율과 여러 분석을 상용화함으로써 예측 기간 동안에도 그 지위를 유지할 것으로 예측됩니다.
기술별로는 높은 처리량 PCR 기술의 이용이 증가하고 있으며, HIV 검사에 NAAT 검사가 권장됨에 따라 분자진단제 분야가 예측 기간 동안 가장 빠른 복합 연간 성장률(CAGR)로 성장할 것으로 추정됩니다. 여러 병원체를 동시에 검출하는 멀티플렉스 PCR 검사의 개발도 STD 진단 산업의 성장에 기여할 것으로 예상됩니다.
용도별로는 HIV 검사 분야가 2023년에 STD 진단 업계를 지배할 것으로 예상됩니다. 이것은 HIV의 높은 이환율, 분자 검사에 대한 제품 승인 증가, 정부의 유리한 노력 등의 요인 때문입니다.
아시아태평양 국가들은 STD 검사율 상승, 가처분 소득 증가, 개발도상국에서의 STD 유병률 증가 등으로 예측 기간 동안 가장 빠른 성장이 예상됩니다.

보급과 성장 전망의 매핑
사용자 시점 분석
규제와 상환의 틀
시장 성장 촉진요인 분석
- 세계적으로 증대하는 성감염증에 의한 질병 부담
- STD 진단에 있어서의 기술의 진보
- 조기 진단과 치료를 장려하는 정부의 대처
시장 성장 억제요인 분석
- 성감염증의 예방접종의 대상 범위
COVID-19의 영향 분석
SWOT 분석, 요인별(정치,법률, 경제, 기술)
업계 분석 - Porter's Five Forces 분석

제4장 STD 진단 시장 : 부문 분석, 제품별(2018년-2030년)

STD 진단 시장 : 제품 변동 분석
장비 및 서비스
소모품
소프트웨어

제5장 STD 진단 시장 : 용도별 부문 분석(2018년-2030년)

STD 진단 시장 : 용도의 변동 분석
Ct/NG검사
매독 검사
HSV 테스트
HPV 검사
HIV 검사
우레아플라스마와 마이코플라스마의 검사
트리코모나스 검사
VZV 테스트
고노로히트테스트
기타 시험

제6장 STD 진단 시장 : 기술별 부문 분석(2018년-2030년)

STD 진단 시장 : 기술 변동 분석
분자진단학
면역 측정법
기타

제7장 STD 진단 시장 : 부문 분석, 검사 장소별(2018년-2030년)

STD 진단 시장 : 검사 장소의 변동 분석
임상 검사
포인트 오브 케어 검사

제8장 STD 진단 시장 : 부문 분석, 지역별(2018년-2030년)

STD 진단 시장 : 지역별 전망
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카

제9장 STD 진단 시장 : 경쟁 분석

주요 시장 진출기업에 의한 최근의 동향과 영향 분석
기업의 분류
벤더 상황
주요 기업의 시장 점유율 분석, 2022년
공개회사
비공개회사
기업 프로파일
- BD
- F. HOFFMANN-LA ROCHE LTD.
- HOLOGIC INC.(GEN PROBE)
- ABBOTT
- CEPHEID(DANAHER)
- QIAGEN
- ORASURE TECHNOLOGIES, INC
- BIO-RAD LABORATORIES, INC.
- THERMO FISHER SCIENTIFIC, INC.
- SEEGENE INC.
- DIASORIN SPA

제10장 결론

BJH

영문 목차

영문목차

STD Diagnostics Market Growth & Trends:

The global STD diagnostics market size is expected to reach USD 16.36 billion by 2030, expanding at a CAGR of 7.18% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing disease burden of Sexually Transmitted Disease (STD) and efforts by government & non-profit organizations to increase awareness and encourage regular screenings among the younger population are the key factors augmenting the market growth. According to WHO data, around 374 million new cases of syphilis, gonorrhea, chlamydia, and trichomoniasis are recorded every year globally.

Development and commercialization of advanced products, such as next-generation HIV testing kits and multiplex PCR products, enable physicians to timely diagnose & distinguish a range of STIs and provide appropriate treatment. Seegene, Inc., a South Korea-based diagnostic company, provides a wide portfolio of Allplex, Anyplex, and Seeplex products that detect various causative agents. For instance, Allplex STI/BV Panel Assay can distinguish 28 causative agents in a single test. In April 2022, Seegene, Inc. announced the development of Allplex HPV HR Detection.

Allplex HPV HR Detection is the world's first commercialized '3 Ct' PCR assay. Seegene is focusing to apply this technology to its entire product chain, including STI, Urinary Tract Infection (UTI), and Respiratory Virus (RV) assays. This strategic technological advancement is expected to provide an additional advantage to the company that can help increase its share in the Sexually Transmitted Disease (STD) diagnostics industry.

The HIV National Strategic Plan is a roadmap for eliminating the human immunodeficiency virus pandemic in the U.S. by 2030. The HIV Plan, which will run from 2021 to 2025, is the country's third five-year national HIV plan in a row, with a 10-year goal of halving new human immunodeficiency virus infections by 90% by 2030. Furthermore, the Viral Hepatitis National Strategic Plan focuses on hepatitis B and C, which are sexually transmitted. In January 2021, the US Department of Health and Human Services (HHS) released a nationwide strategy to address the preventable, substantial public health threats posed by viral hepatitis in the United States. The government's beneficial actions create a favorable atmosphere for the expansion of the STD diagnostics industry.

Companies are engaging in strategic initiatives that aid in the development of new products, and regulatory approvals as well as enhance their STD diagnostics product portfolio. For instance, in August 2020, DiaSorin, Inc. received 510 (k) approval from U.S. FDA for introducing LIAISON XL MUREX anti-HBe. It is used for the diagnosis of HBV infection. This immunoassay product works on the principle of chemiluminescence.

STD Diagnostics Market Report Highlights:

In 2023, the consumables segment accounted for the largest market share and is anticipated to maintain its position over the forecast period owing to high testing rates for the diagnosis of STDs and the commercialization of several assays
Based on technology, the molecular diagnostics segment is estimated to grow at the fastest CAGR during the forecast period owing to the increasing use of high-throughput PCR technology and the recommendation of NAAT tests for HIV testing. The development of multiplex PCR tests for the simultaneous detection of multiple pathogens is also expected to contribute to the STD diagnostics industry's growth
Based on application, the HIV testing segment is expected to dominate the STD diagnostics industry in 2023, due to factors such as the high incidence rate of the disease, increasing product approvals for molecular tests, and favorable government initiatives
Asia Pacific region is anticipated to experience the fastest growth over the forecast period due to an increase in testing rates for STDS, a rise in disposable income, and high disease prevalence of STD in developing countries

Chapter 1 Methodology and Scope

1.1 Market Segmentation and Scope
- 1.1.1 Segment Scope
- 1.1.2 Regional Scope
- 1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
- 1.3.1 Purchased Database:
- 1.3.2 Gvr's Internal Database
- 1.3.3 Secondary Sources
- 1.3.4 Primary Research
- 1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
- 1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
- 1.6.1 Commodity Flow Analysis
  - 1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List Of Secondary Sources
1.9 List Of Abbreviations
1.10 Objectives
- 1.10.1 Objective 1
- 1.10.2 Objective 2
- 1.10.3 Objective 3
- 1.10.4 Objective 4

Chapter 2 Executive Summary

2.1 Market Outlook
2.2 Product And Application Snapshot
2.3 Technology And Location Of Testing Snapshot
2.4 Competitive Snapshot

Chapter 3 STD Diagnostics Market Variables, Trends, And Scope

3.1 Penetration And Growth Prospect Mapping
3.2 User Perspective Analysis
3.3 Regulatory And Reimbursement Framework
3.4 Market Driver Analysis
- 3.4.1 Growing Global Disease Burden Of STDs
- 3.4.2 Technological Advancements In STD Diagnostics
- 3.4.3 Government Initiatives Encouraging Early Diagnosis And Treatment
3.5 Market Restraint Analysis
- 3.5.1 Vaccination Coverage For STDs
3.6 Covid-19 Impact Analysis
3.7 Swot Analysis, By Factor (Political & Legal, Economic, And Technological)
3.8 Industry Analysis - Porter's

Chapter 4 STD Diagnostics Market: Segment Analysis, By Product, 2018 - 2030 (USD Million)

4.1 STD Diagnostics Market: Product Movement Analysis
4.2 Instruments And Services
- 4.2.1 Instruments And Services Market, 2018 - 2030 (USD Million)
4.3 Consumables
- 4.3.1 Consumables Market, 2018 - 2030 (USD Million)
4.4 Software
- 4.4.1 Software Market, 2018 - 2030 (USD Million)

Chapter 5 STD Diagnostics Market: Segment Analysis, By Application, 2018 - 2030 (USD Million)

5.1 STD Diagnostics Market: Application Movement Analysis
5.2 Ct/Ng Testing
- 5.2.1 Ct/Ng Testing Market, 2018 - 2030 (USD Million)
5.3 Syphilis Testing
- 5.3.1 Syphilis Testing Market, 2018 - 2030 (USD Million)
- 5.3.2 Syphilis Pcr Testing Market, 2018 - 2030 (USD Million)
- 5.3.3 Syphilis Non-Pcr Testing Market, 2018 - 2030 (USD Million)
5.4 Hsv Testing
- 5.4.1 Hsv Testing Market, 2018 - 2030 (USD Million)
- 5.4.2 Herpes Simplex Virus Pcr Testing Market, 2018 - 2030 (USD Million)
- 5.4.3 Herpes Simplex Virus Non-Pcr Testing Market, 2018 - 2030 (USD Million)
5.5 Hpv Testing
- 5.5.1 Hpv Testing Market, 2018 - 2030 (USD Million)
5.6 Hiv Testing
- 5.6.1 Human Immunodeficiency Virus Testing Market, 2018 - 2030 (USD Million)
5.7 Ureaplasma & Mycoplasma Testing
- 5.7.1 Ureaplasma & Mycoplasma Testing Market, 2018 - 2030 (USD Million)
5.8 Trichomonas Testing
- 5.8.1 Trichomonas Testing Market, 2018 - 2030 (USD Million)
5.9 Vzv Testing
- 5.9.1 Vzv Testing Market, 2018 - 2030 (USD Million)
- 5.9.2 Vzv Pcr Testing Market, 2018 - 2030 (USD Million)
- 5.9.3 Vzv Non-Pcr Testing Market, 2018 - 2030 (USD Million)
5.10 Gonorrheatesting
- 5.10.1 Gonorrhea Testing Market, 2018 - 2030 (USD Million)
5.11 Other Testing
- 5.11.1 Other Testing Market, 2018 - 2030 (USD Million)

Chapter 6 STD Diagnostics Market: Segment Analysis, By Technology, 2018-2030 (USD Million)

6.1 STD Diagnostics Market: Technology Movement Analysis
6.2 Molecular Diagnostics
- 6.2.1 Molecular Diagnostics Market, 2018 - 2030 (USD Million)
6.3 Immunoassay
- 6.3.1 Immunoassay Market, 2018 - 2030 (USD Million)
6.4 Others
- 6.4.1 Others Market, 2018 - 2030 (USD Million)

Chapter 7 STD Diagnostics Market: Segment Analysis, By Location Of Testing, 2018 - 2030 (USD Million)

7.1 STD Diagnostics Market: Location Of Testing Movement Analysis
7.2 Laboratory Testing
- 7.2.1 Laboratory Testing Market, 2018 - 2030 (USD Million)
- 7.2.2 Commercial/Private Labs
  - 7.2.2.1 Commercial/Private Labs Market, 2018 - 2030 (USD Million)
- 7.2.3 Public Health Labs
  - 7.2.3.1 Public Health Labs Market, 2018 - 2030 (USD Million)
7.3 Point Of Care Testing
- 7.3.1 Point Of Care Testing Market, 2018 - 2030 (USD Million)

Chapter 8 STD Diagnostics Market: Segment Analysis, By Region, 2018 - 2030 (USD Million)

8.1 STD Diagnostics Market: Regional Outlook
8.2 North America
- 8.2.1 North America STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.2.2 U.S.
  - 8.2.2.1 Key Country Dynamics
  - 8.2.2.2 U.S. STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  - 8.2.2.3 Target Disease: Cancer Incidence
  - 8.2.2.4 Market And Competitive Scenario
  - 8.2.2.5 Regulatory Framework
  - 8.2.2.6 Reimbursement Scenario
- 8.2.3 Canada
  - 8.2.3.1 Key Country Dynamics
  - 8.2.3.2 Canada STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  - 8.2.3.3 Target Disease: Cancer Incidence
  - 8.2.3.4 Market And Competitive Scenario
  - 8.2.3.5 Regulatory Framework
  - 8.2.3.6 Reimbursement Scenario
8.3 Europe
- 8.3.1 Europe STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.3.2 UK
  - 8.3.2.1 Key Country Dynamics
  - 8.3.2.2 Uk STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  - 8.3.2.3 Target Disease Prevalence
  - 8.3.2.4 Market And Competitive Scenario
  - 8.3.2.5 Regulatory Framework
  - 8.3.2.6 Reimbursement Scenario
- 8.3.3 Germany
  - 8.3.3.1 Key Country Dynamics
  - 8.3.3.2 Germany STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  - 8.3.3.3 Target Disease Prevalence
  - 8.3.3.4 Market And Competitive Scenario
  - 8.3.3.5 Regulatory Framework
  - 8.3.3.6 Reimbursement Scenario
- 8.3.4 France
  - 8.3.4.1 Key Country Dynamics
  - 8.3.4.2 France STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  - 8.3.4.3 Target Disease Prevalence
  - 8.3.4.4 Market And Competitive Scenario
  - 8.3.4.5 Regulatory Framework
  - 8.3.4.6 Reimbursement Scenario
- 8.3.5 Spain
  - 8.3.5.1 Key Country Dynamics
  - 8.3.5.2 Spain STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  - 8.3.5.3 Target Disease Prevalence
  - 8.3.5.4 Market And Competitive Scenario
  - 8.3.5.5 Regulatory Framework
  - 8.3.5.6 Reimbursement Scenario
- 8.3.6 Italy
  - 8.3.6.1 Key Country Dynamics
  - 8.3.6.2 Italy STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  - 8.3.6.3 Target Disease Prevalence
  - 8.3.6.4 Market And Competitive Scenario
  - 8.3.6.5 Regulatory Framework
  - 8.3.6.6 Reimbursement Scenario
- 8.3.7 Denmark
  - 8.3.7.1 Key Country Dynamics
  - 8.3.7.2 Denmark STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  - 8.3.7.3 Target Disease Prevalence
  - 8.3.7.4 Market And Competitive Scenario
  - 8.3.7.5 Regulatory Framework
  - 8.3.7.6 Reimbursement Scenario
- 8.3.8 Sweden
  - 8.3.8.1 Key Country Dynamics
  - 8.3.8.2 Sweden STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  - 8.3.8.3 Target Disease Prevalence
  - 8.3.8.4 Market And Competitive Scenario
  - 8.3.8.5 Regulatory Framework
  - 8.3.8.6 Reimbursement Scenario
- 8.3.9 Norway
  - 8.3.9.1 Key Country Dynamics
  - 8.3.9.2 Norway STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  - 8.3.9.3 Target Disease Prevalence
  - 8.3.9.4 Market And Competitive Scenario
  - 8.3.9.5 Regulatory Framework
  - 8.3.9.6 Reimbursement Scenario
- 8.3.10 Rest Of Europe STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4 Asia Pacific
- 8.4.1 Asia Pacific STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.4.2 Japan
  - 8.4.2.1 Key Country Dynamics
  - 8.4.2.2 Japan STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  - 8.4.2.3 Target Disease Prevalence
  - 8.4.2.4 Market And Competitive Scenario
  - 8.4.2.5 Regulatory Framework
  - 8.4.2.6 Reimbursement Scenario
- 8.4.3 China
  - 8.4.3.1 Key Country Dynamics
  - 8.4.3.2 China STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  - 8.4.3.3 Target Disease Prevalence
  - 8.4.3.4 Market And Competitive Scenario
  - 8.4.3.5 Regulatory Framework
  - 8.4.3.6 Reimbursement Scenario
- 8.4.4 India
  - 8.4.4.1 Key Country Dynamics
  - 8.4.4.2 India STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  - 8.4.4.3 Target Disease Prevalence
  - 8.4.4.4 Market And Competitive Scenario
  - 8.4.4.5 Regulatory Framework
  - 8.4.4.6 Reimbursement Scenario
- 8.4.5 Australia
  - 8.4.5.1 Key Country Dynamics
  - 8.4.5.2 Australia STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  - 8.4.5.3 Target Disease Prevalence
  - 8.4.5.4 Market And Competitive Scenario
  - 8.4.5.5 Regulatory Framework
  - 8.4.5.6 Reimbursement Scenario
- 8.4.6 Thailand
  - 8.4.6.1 Key Country Dynamics
  - 8.4.6.2 Thailand STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  - 8.4.6.3 Target Disease Prevalence
  - 8.4.6.4 Market And Competitive Scenario
  - 8.4.6.5 Regulatory Framework
  - 8.4.6.6 Reimbursement Scenario
- 8.4.7 South Korea
  - 8.4.7.1 Key Country Dynamics
  - 8.4.7.2 South Korea STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  - 8.4.7.3 Target Disease Prevalence
  - 8.4.7.4 Market And Competitive Scenario
  - 8.4.7.5 Regulatory Framework
  - 8.4.7.6 Reimbursement Scenario
- 8.4.8 Rest Of Asia Pacific STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5 Latin America
- 8.5.1 Latin America STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5.2 Brazil
  - 8.5.2.1 Key Country Dynamics
  - 8.5.2.2 Brazil STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  - 8.5.2.3 Target Disease Prevalence
  - 8.5.2.4 Competitive Scenario
  - 8.5.2.5 Regulatory Framework
  - 8.5.2.6 Reimbursement Scenario
- 8.5.3 Mexico
  - 8.5.3.1 Key Country Dynamics
  - 8.5.3.2 Mexico STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  - 8.5.3.3 Target Disease Prevalence
  - 8.5.3.4 Competitive Scenario
  - 8.5.3.5 Regulatory Framework
  - 8.5.3.6 Reimbursement Scenario
- 8.5.4 Argentina
  - 8.5.4.1 Key Country Dynamics
  - 8.5.4.2 Argentina STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  - 8.5.4.3 Target Disease Prevalence
  - 8.5.4.4 Competitive Scenario
  - 8.5.4.5 Regulatory Framework
  - 8.5.4.6 Reimbursement Scenario
- 8.5.5 Rest Of Latin America STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6 Mea
- 8.6.1 Mea STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.6.2 South Africa
  - 8.6.2.1 Key Country Dynamics
  - 8.6.2.2 South Africa STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  - 8.6.2.3 Target Disease Prevalence
  - 8.6.2.4 Competitive Scenario
  - 8.6.2.5 Regulatory Framework
  - 8.6.2.6 Reimbursement Scenario
- 8.6.3 Saudi Arabia
  - 8.6.3.1 Key Country Dynamics
  - 8.6.3.2 Saudi Arabia STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  - 8.6.3.3 Target Disease Prevalence
  - 8.6.3.4 Competitive Scenario
  - 8.6.3.5 Regulatory Framework
  - 8.6.3.6 Reimbursement Scenario
- 8.6.4 UAE
  - 8.6.4.1 Key Country Dynamics
  - 8.6.4.2 Uae STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  - 8.6.4.3 Target Disease Prevalence
  - 8.6.4.4 Competitive Scenario
  - 8.6.4.5 Regulatory Framework
  - 8.6.4.6 Reimbursement Scenario
- 8.6.5 Kuwait
  - 8.6.5.1 Key Country Dynamics
  - 8.6.5.2 Kuwait STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  - 8.6.5.3 Target Disease Prevalence
  - 8.6.5.4 Competitive Scenario
  - 8.6.5.5 Regulatory Framework
  - 8.6.5.6 Reimbursement Scenario
- 8.6.6 Rest Of Mea STD Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9 STD Diagnostics Market: Competitive Analysis

9.1 Recent Developments And Impact Analysis, By Key Market Participants
- 9.1.1 New Product Launches
- 9.1.2 Mergers And Acquisitions
- 9.1.3 Partnerships And Strategic Collaboration
- 9.1.4 Conferences And Campaigns
9.2 Company Categorization
- 9.2.1 Innovators
- 9.2.2 Market Leaders
- 9.2.3 Heat Map Analysis
9.3 Vendor Landscape
- 9.3.1 List Of Key Distributors And Channel Partners
- 9.3.2 Key Customers
9.4 Key Company Market Share Analysis, 2022
9.5 Public Companies
- 9.5.1 Company Market Position Analysis
- 9.5.2 Competitive Dashboard Analysis
  - 9.5.2.1 Market Differentiators
9.6 Private Companies
- 9.6.1 List Of Key Emerging Companies
- 9.6.2 Regional Network Map
9.7 Company Profiles
- 9.7.1 BD
  - 9.7.1.1 Company Overview
  - 9.7.1.2 Financial Performance
  - 9.7.1.3 Product benchmarking
  - 9.7.1.4 Strategic initiatives
- 9.7.2 F. HOFFMANN-LA ROCHE LTD.
  - 9.7.2.1 Company overview
  - 9.7.2.2 Financial Performance
  - 9.7.2.3 Product benchmarking
  - 9.7.2.4 Strategic initiatives
- 9.7.3 HOLOGIC INC. (GEN PROBE)
  - 9.7.3.1 Company Overview
  - 9.7.3.2 Financial Performance
  - 9.7.3.3 Product Benchmarking
  - 9.7.3.4 Strategic Initiatives
- 9.7.4 ABBOTT
  - 9.7.4.1 Company Overview
  - 9.7.4.2 Financial Performance
  - 9.7.4.3 Product Benchmarking
  - 9.7.4.4 Strategic Initiatives
- 9.7.5 CEPHEID (DANAHER)
  - 9.7.5.1 Company Overview
  - 9.7.5.2 Financial Performance
  - 9.7.5.3 Product Benchmarking
  - 9.7.5.4 Strategic Initiatives
- 9.7.6 QIAGEN
  - 9.7.6.1 Company Overview
  - 9.7.6.2 Financial Performance
  - 9.7.6.3 Product Benchmarking
  - 9.7.6.4 Strategic Initiatives
- 9.7.7 ORASURE TECHNOLOGIES, INC
  - 9.7.7.1 Company Overview
  - 9.7.7.2 Financial Performance
  - 9.7.7.3 Product Benchmarking
  - 9.7.7.4 Strategic Initiatives
- 9.7.8 BIO-RAD LABORATORIES, INC.
  - 9.7.8.1 Company Overview
  - 9.7.8.2 Financial Performance
  - 9.7.8.3 Product Benchmarking
  - 9.7.8.4 Strategic Initiatives
- 9.7.9 BIOMERIEUX SA
  - 9.7.9.1 Company overview
  - 9.7.9.2 Financial Performance
  - 9.7.9.3 Product benchmarking
  - 9.7.9.4 Strategic initiatives
- 9.7.10 THERMO FISHER SCIENTIFIC, INC.
  - 9.7.10.1 Company overview
  - 9.7.10.2 Financial performance
  - 9.7.10.3 Product benchmarking
  - 9.7.10.4 Strategic initiatives
- 9.7.11 SEEGENE INC.
  - 9.7.11.1 Company overview
  - 9.7.11.2 Financial performance
  - 9.7.11.3 Product benchmarking
  - 9.7.11.4 Strategic initiatives
- 9.7.12 DIASORIN S.P.A
  - 9.7.12.1 Company overview
  - 9.7.12.2 Financial performance
  - 9.7.12.3 Product benchmarking
  - 9.7.12.4 Strategic initiatives